August 01, 2023
AstraZeneca has set aside $510 million to resolve Bristol-Myers Squibb Co.'s litigation that it infringed cancer treatment patents to create rival immunotherapy drugs, according to a recent securities filing.
July 31, 2023
A Delaware federal judge on Monday dismissed Bristol-Myers Squibb Co.'s litigation accusing AstraZeneca of infringing cancer treatment patents to create a rival immunotherapy drug, after the pharmaceutical giants reached an agreement.